stars 1 stars 2 stars 3

CheckmAb Srl is an innovative start-up biotech company focused on the development of novel monoclonal antibodies for cancer immunotherapy, with the aim to provide safer and more effective therapies for patients. At present, the company is focused on the development of monoclonal antibodies for cancer immunotherapy, specifically targeting tumor-infiltrating regulatory T lymphocytes. These antibodies are expected to unleash the immunological response only within the neoplastic lesion, thereby avoiding harmful systemic autoimmune reactions that are too often associated with current immuntoherapies.

Checkmab S.r.l. Questions

The Checkmab S.r.l. annual revenue was $1 million in 2026.

Marco Venturelli is the Chairman of Checkmab S.r.l..

7 people are employed at Checkmab S.r.l..

Checkmab S.r.l. is based in Milan, Lombardy.

The NAICS codes for Checkmab S.r.l. are [541, 54].

The SIC codes for Checkmab S.r.l. are [87, 873].

Top Checkmab S.r.l. Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users